What dose of enclomiphene do trials use?

Strengths and whether there is a label
SourceFormStrengths
FDA committee transcript (proposed dosage forms for compounding)Capsules or tablets12.5, 25 and 50 mg5
Wiehle 2013, phase II (forty-eight men)Capsules6.25, 12.5 and 25 mg12
Wiehle 2014, phase IIb (83 enrolled)Capsules12.5 and 25 mg3

Strengths and whether there is a label

The table is set at the top of the page

The EMA's committee adopted a negative opinion on EnCyzix capsules on 25 January 2018, and its marketing authorisation was refused.6 At the 8 June 2022 FDA compounding committee meeting, FDA proposed that enclomiphene citrate not be included on the 503A Bulks List; the vote was 4 yes and 8 no.7 Searches of DailyMed, the EMA and the FDA documents returned no approved label to quote a dose from. The BSSM statement says enclomiphene is not currently approved by the FDA or the EMA, and its manufacturer discontinued development in 2021.8

A retrospective case series of 15 men describes a compounded sublingual liquid, 1 mL holding enclomiphene citrate 25 mg, held under the tongue for 30 to 60 seconds once daily for 60 days.9 Searches of DailyMed, the FDA transcript and PubMed found no injectable concentration or syringe use for enclomiphene.

What the trials used, arm by arm

TrialDose and schedulePeopleLength
Wiehle 2013, phase II6.25, 12.5 or 25 mg daily, or transdermal testosterone daily182Forty-eight men, forty-four completed per protocol6 weeks
Kaminetsky 2013, phase IIB, open-labelOral enclomiphene citrate against topical testosterone gel; dose not in the saved text10212 men6 months
Wiehle 2014, phase IIb (NCT01270841)12.5 mg or 25 mg Androxal, 1x daily, against placebo or open-label Testim383 enrolled in the registry; a review gives 124 enrolled and 73 completing323 months3
Phase III registry entry NCT0199322512.5 mg or 25 mg Androxal, against placebo or AndroGel 1.62%4120 overweight men aged 18 to 60 enrolled416 weeks4
Kim 2016, phase III (two parallel studies, ZA-304 and ZA-305)Two doses: 12.5 and 25 mg in a review table2, 12.5 mg or 12.5 mg uptitrated to 25 mg in the FDA transcript5; against AndroGel 1.62% and placebo11265 men in a review table216 weeks11

Arm sizes for the phase III studies are not in the saved texts.

Route, schedule, stepping and duration

The EMA says EnCyzix was to be available as capsules to be taken by mouth.6 In the Wiehle 2013 phase II study, men taking enclomiphene citrate were instructed to take one capsule of blinded study medication between 7:00 h and 10:00 h every day.12 A review and the FDA transcript give a half-life of about 10 hours; the Wiehle paper cites about 7 h.251

The BSSM statement describes beginning at 6.25 mg daily, increasing weekly as tolerated up to 25 mg daily, and says the dosage may be further increased to 50 mg daily if there is an inadequate clinical or biochemical response.8 It says that, as enclomiphene is unlicensed in the UK and lacks long-term data, use is limited to experienced clinicians in specialist or research settings.8 The FDA transcript gives the dosing of Kim et al.'s trials as 12.5 milligram or 12.5 uptitrated to 25 milligram; the uptitration rule is not in the saved texts.5

A meta-analysis of seven studies of clomiphene citrate or enclomiphene citrate gives treatment lasting 1.5 to 4 months, the 12-man Kaminetsky 2013 study reports testosterone at 6 months, and a retrospective study of 66 men reports a median enclomiphene treatment of 8.9 months.121013

Storage

The FDA transcript says enclomiphene is expected to be stable under ordinary storage conditions when protected from light in the proposed form.5 It gives no beyond-use date or storage after mixing.

Frequently asked questions

What is the highest enclomiphene dose studied?

A meta-analysis of seven studies in 292 men with obesity-related functional androgen deficiency, treated with clomiphene or enclomiphene, gives enclomiphene citrate doses of 12.5 to 25 mg daily, and the FDA transcript says Cmax increased in a less than dose proportional manner from 25 to 50 milligram.125 The BSSM statement gives 50 mg daily after an inadequate response, and a case report describes atrial flutter in a man who inadvertently took 50 mg daily in place of 25 mg daily, with causality not established.814

What dose is used on TRT or after a cycle?

Searches of PubMed and the FDA transcript found no enclomiphene dosing for men on TRT or after an anabolic cycle; the 12-man Kaminetsky 2013 study enrolled men previously treated with topical testosterone.10

What side effects do the regulators and trials state?

FDA reviewers listed inability to climax, loss of sensation during intercourse and GI symptoms at 25 mg in a trial comparing 12.5 and 25 mg with topical testosterone and placebo, considered possibly related to the study drug, after which both patients discontinued, and serious events including atrial flutter, pulmonary embolism and deep vein thrombosis in a safety study of 12.5 mg and 12.5 mg uptitrated to 25 mg.5 The EMA listed a risk of venous thromboembolism.6

References

  1. PubMed Central. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. 2013. pmc.ncbi.nlm.nih.gov
  2. Expert Opin Pharmacother. Enclomiphene Citrate for the Treatment of Secondary Male Hypogonadism. 2016. pmc.ncbi.nlm.nih.gov
  3. ClinicalTrials.gov. NCT01270841: Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism. 2014. clinicaltrials.gov
  4. ClinicalTrials.gov. NCT01993225: A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%. 2014. clinicaltrials.gov
  5. US FDA. FDA Meeting. fda.gov
  6. European Medicines Agency. EnCyzix | European Medicines Agency (EMA). ema.europa.eu
  7. US FDA. NDA 210693. fda.gov
  8. World J Mens Health. British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism. 2026. pmc.ncbi.nlm.nih.gov
  9. Cureus. Changes in Serum Testosterone After Sublingual Enclomiphene Citrate Combined With a Mineral Oxide Delivery System: A Retrospective Case Series of 15 Men. 2026. pmc.ncbi.nlm.nih.gov
  10. PubMed. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. 2013. pubmed.ncbi.nlm.nih.gov
  11. PubMed. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. 2016. pubmed.ncbi.nlm.nih.gov
  12. PubMed. Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis. 2023. pubmed.ncbi.nlm.nih.gov
  13. Transl Androl Urol. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. 2024. pmc.ncbi.nlm.nih.gov
  14. PubMed. Newly Detected Atrial Flutter After Enclomiphene Dose Escalation in a Patient With Prior Mitral Valve Repair and Chronic Immune Thrombocytopenia: A Case Report. 2026. pubmed.ncbi.nlm.nih.gov